Oral Communication  
Session/Topic: Hepatitis: basic science and virology

N. OC 29  
Title: The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocytes trajectories in HIV/HCV coinfected patients: data from the Icona Foundation Cohort

Authors: A. Bandera1, P. Lorenzini2, G. Lapadula1, C. Mussini1, A. Saracino3, F. CECCHERINI-SILBERSTEIN4, M. Puoti5, E. QUIROS-ROLDAN1, F. MONTAGNANI1, A. ANTONI{2, A. GORI, A. D’ARMINIO MONFORTE5, for the Icona Foundation Cohort

Affiliation:  
1Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy, 2HIV/AIDS Clinical Department, National Institute for Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy, 3Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy, 4Institute of Infectious Disease, University of Bari, Bari, Italy, 5Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, 6Department of Infectious Diseases, Grande Ospedale Metropolitano Niguarda, Milan, Italy, 7Infectious Diseases, Spedali Civili Hospital, Brescia, Italy, 8University Division of Infectious Diseases, Hospital Department of Specialized and Internal Medicine, Siena, Italy, 9Department of Health Sciences, Clinic of Infectious and Tropical Diseases, University of Milan, Milan, Italy

Abstract:  
Background: HCV coinfection has been recognized as a possible contributor of poor CD4+ recovery under antiretrovirals (ART) and is known to promote systemic inflammation with accumulation of highly differentiated CD8+ T cells. We aimed to study immunological changes after direct-acting antiviral treatment (DAA) in HIV/HCV patients (pts) who achieved sustained virological response (SVR).

Methods: HIV/HCV pts in ICONA/Hepaicona cohort, treated with DAA since Apr 2013 who achieved SVR12, on ART for>12 months, with undetectable HIV-RNA at DAA start, and with available CD4+, CD8+ counts, HIV-RNA before and after DAA were included. Follow-up accrued from the first undetectable viremia before DAA to last visit or first value of HIV-RNA>200 cp/ml after DAA. Piecewise mixed effect linear regression with random slope and intercept was used to model CD4+ and CD8+ trajectories before and after DAA. The following confounders were considered for an association with the intercept: age, sex, epidemiology, nationality, CD4 nadir, CD4 count at DAA start, previous AIDS diagnosis, HCV genotype, HIV-RNA at DAA start, type of DAA, change of ART pre-DAA, use of ribavirin, F4 at DAA start.

Results: A total of 726 HIV/HCV pts were included and contributed for 7,513 values (mean 10/pt). Median follow-up was 2 years (IQR 0.6-10) and 1.6 years (IQR 1-2) before and after DAA. Median age was 53 (IQR: 50-55) years, 22% females, 76% acquired HIV through IVDU. Nadir CD4+ T cell count was <200/mmc in 19% of pts, while CD4+ T cell count at DAA start was >500/mmc in 59%, 350-500/mmc in 19% and <350/mmc in 22% of pts. Median time of ART use at DAA start was 6.4 years (IQR: 2.6-10.9). At DAA start, NRTI + INSTI was the most represented ART (33.8%), followed by NRTI+NNRTI (18.3%) and NRTI+PI (18.4%). Fifty-eight percent of pts had g1, 23% g3 and 17% g4. A stiffness >12.5 kPa was reported in 42% of pts and median HIV-RNA at DAA start was 6 log10 UI/mL (IQR:5.3-6.4). More frequent DAA combinations included sofosbuvir+ledipasvir (36%), sofosbuvir+daclatasvir (24.3%) and sofosbuvir+velpatasvir (2.7%). Globally, ribavirin was used in 57.3% of pts. Duration of DAA was 8 weeks in 2.1%, 12 weeks in 58.7% and 24 weeks in 39.3% of pts. After treatment with DAA, CD4+ continued to increase, but at a significantly slower rate (on average, CD4 increased by 19.1 cells/year less than the rate observed before treatment with DAA, p<0.01 after adjustment for confounders). Conversely, after DAA treatment, a significant steeper decline of CD8+ T cells was observed (on average, CD8 decreased by 66.9 cells/year more than the rate observed before DAA, p<0.01 after adjustment for confounders) (Figure 1).

Conclusions: DAA treatment in HCV/HIV patients does not show a beneficial effect on CD4+ T cells recovery. However, a more rapid CD8+ T cell reduction was found after HCV eradication, possibly justified by removal of antigenic trigger and reflecting amelioration of systemic inflammation.
Figure 1. Slope of CD4+ T cell count (A) and CD8+ T cell count (B) before and after DAA treatment.